Stockscreener 앱 받기
2.09
0.95%
-0.02
시간 외 거래:
2.08
-0.010
-0.48%
전일 마감가:
$2.11
열려 있는:
$2.14
하루 거래량:
495.67K
Relative Volume:
0.41
시가총액:
$376.94M
수익:
$109.16M
순이익/손실:
$-107.78M
주가수익비율:
-1.8892
EPS:
-1.1063
순현금흐름:
$-95.45M
1주 성능:
-4.57%
1개월 성능:
-9.91%
6개월 성능:
-21.13%
1년 성능:
+234.08%
1일 변동 폭
$2.08
$2.215
1주일 범위
$2.08
$2.26
52주 변동 폭
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
명칭
Century Therapeutics Inc
전화
215-981-4000
주소
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.09 | 380.55M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | TD Cowen | Buy |
| 2024-08-08 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 개시 | Chardan Capital Markets | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-05-23 | 개시 | H.C. Wainwright | Buy |
| 2022-05-12 | 개시 | William Blair | Mkt Perform |
| 2021-07-13 | 개시 | BofA Securities | Buy |
| 2021-07-13 | 개시 | JP Morgan | Overweight |
| 2021-07-13 | 개시 | Piper Sandler | Overweight |
모두보기
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
Century Therapeutics Inc (IPSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Century Therapeutics Inc (IPSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
IPSC|Century Therapeutics Inc|Price:2.110|Chg%:-0.060 - TradingKey
Century Therapeutics, Inc. Revenue Breakdown – NASDAQ:IPSC - TradingView
IPSC stock trades steadily as Century Therapeutics updates its pipeline and cash runway - Ad-hoc-news.de
IPSC stock trades around recent lows as Century Therapeutics weighs pipeline and cash burn - Ad-hoc-news.de
Century Therapeutics (IPSC) Dips 2.7% as Shares Near Key Support ZoneDividend Stock Picks - dars.gov.et
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses - Yahoo Finance
Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential - Seeking Alpha
Century Therapeutics abstracts accepted for diabetes conferences - Investing.com
Century Therapeutics abstracts accepted for diabetes conferences By Investing.com - Investing.com South Africa
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026 - Investing News Network
Century Therapeutics (IPSC) Q1 2026 Earnings: Narrower Loss Surprises, Shares ClimbEarnings Growth Analysis - dars.gov.et
Frontier tech research, news & data - MLQ.ai
IPSC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEstimate Dispersion - dars.gov.et
IPSCCentury Therapeutics Inc Short Interest - Finviz
Price to sales forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
IPSC News | CENTURY THERAPEUTICS INC (NASDAQ:IPSC) - ChartMill
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Index - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Value Benchmark - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM:IPSC) added to Russell Microcap Value Benchmark Index - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell Microcap Index - marketscreener.com
Century Therapeutics (IPSC) Holds Support With Modest Gain Amid Biotech Sector UncertaintyVirgin POC - dars.gov.et
Century Therapeutics, Inc. Actuals & Estimates (NASDAQ:IPSC) - TradingView
Enterprise value to EBIT forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Price to earnings forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
IPSC Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Century Therapeutics updates its CAR-T pipeline, shares trade on Nasdaq - Ad-hoc-news.de
Century Therapeutics Inc (IPSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Century Therapeutics Inc. (IPSC) Edges Higher as Biotech Stock Tests Key Resistance ZoneGap and Go - dars.gov.et
Century Therapeutics Inc (IPSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Century Therapeutics Inc (IPSC) Institutional Confidence - TradingKey
Century Therapeutics Inc (IPSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Century Therapeutics Inc (IPSC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Century Therapeutics Inc (IPSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Century Therapeutics Inc (IPSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Century Therapeutics amends chief scientific officer contract to part-time role By Investing.com - Investing.com South Africa
Century Therapeutics amends chief scientific officer contract to part-time role - Investing.com India
Century retains Chad Cowan as part-time Chief Scientific Officer with reduced pay - TradingView
Century Therapeutics (IPSC) shifts Chief Scientific Officer to part-time role with new pay terms - Stock Titan
Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com - Investing.com India
Century Therapeutics SVP Carr sells $3,691 in company stock - Investing.com
Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com - Investing.com Nigeria
Century Therapeutics executive Gregory Russotti sells $5,767 in stock - Investing.com
Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding - Stock Titan
Tax-related share sale by Century Therapeutics (IPSC) SVP Carr - Stock Titan
Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting - Stock Titan
Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings - Stock Titan
Century Therapeutics Inc (IPSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):